Potential applications of gene therapy in the patient with cancer

Drugs and Aging

Volumn 17, Issue 2, 2000, Pages 121-132

  Szlosarek, Piotr W ^a   Dalgleish, Angus G ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; CANCER; CLONING VECTOR; GENE FUNCTION; GENE THERAPY; HUMAN; IMMUNOMODULATION; LIFE EXPECTANCY; MORBIDITY; PRIORITY JOURNAL; REVIEW; SUICIDE GENE;

EID: 0033852615     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200017020-00004     Document Type: Review

References (143)

1. 1. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans: immunotherapy of patients with advanced melanoma using tumor infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570-8
2. 2. Blaese RM, Culver KW, Miller AD, et al. T-lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995; 270: 475-80
3. 3. Eliasson MJL, Sampei K, Mandir AS, et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischaemia. Nat Med 1997; 3: 1089-95
4. 4. Stenbit AE, Tsu-Shuen T, Li J, et al. GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes. Nat Med 1997; 3: 1096-101
5. 5. Carroll JL, Bell MC, Gameau LJ, et al. Analysis of a bystander effect in vivo following adenovirus-based p53 gene therapy [abstract]. Proc Am Assoc Cancer Res 1999; 40: 3280
6. 6. Caruso M, Panis Y, Gagandeep S, et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci U S A 1993; 90: 7024-8
7. 7. Wei MX, Tamiya T, Rhee RJ, et al. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res 1995; 1: 1171-7
8. 8. Elshami AA, Saavendra A, Zhang H, et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996; 3: 85-92
9. 9. Vile RG, Castledon S, Marshall J, et al. Generation of an antitumour response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoral cytokine expression. Int J Cancer 1997; 71: 267-74
10. 10. Nishizaki M, Fujiwara T, Tanida T, et al. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin Cancer Res 1999; 5: 1015-23
11. 11. Patel PI. Identification of disease genes and somatic gene therapy: an overview and prospects for the aged. J Gerontology 1993; 48: B80-5
12. 12. Blaese M, Blankenstein T, Brenner M, et al. Vectors in cancer therapy: how will they deliver? Cancer Gene Ther 1995; 2: 291-7
13. 13. Nabel GJ. Development of optimized vectors for gene therapy. Proc Natl Acad Sci U S A 1999; 96: 324-6
14. 14. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997; 89: 21-39
15. 15. Dranoff G. Cancer gene therapy: connecting basic research with clinical inquiry. J Clin Oncol 1998; 16: 2548-56
16. 16. Anderson WF. Human gene therapy. Nature 1998; 392 Suppl.: 25-30
17. 17. Patterson A, Harris AL. Molecular chemotherapy for breast cancer. Drugs Aging 1999; 14: 75-90
18. 18. Clayman GL, El-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16: 2221-32
19. 19. Kirn D, Hermiston T, McCormick F. ONYX-015: clinical data are encouraging. Nat Med 1998; 4: 1341-2
20. 20. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54: 2287-91
21. 21. Pirollo KF, Hao Z, Rait A, et al. p53-mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997; 14: 1735-46
22. 22. Donahue RE, Kessler SW, Bodine D, et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 1992; 176: 1125-35
23. 23. Wang Q, Finer MH. Second-generation adenovirus vectors. Nat Med 1996; 2: 714-6
24. 24. Nevins JR. Mechanism of activation of early viral transcription by the adenovirus E1A gene product. Cell 1981; 26: 213-20
25. 25. Halbert DN, Cutt JR, Shenk T. Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J Virol 1985; 56: 250-7
26. 26. Gorziglia MI, Lapacevich C, Roy S, et al. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3. J Virol 1999; 73: 6048-55
27. 27. Muruve DA, Barnes MJ, Stillman IE, et al. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependenl hepatic injury in vivo. Hum Gene Ther 1999; 10: 965-76
28. 28. Dewey RA, Morrissey G, Cowsill CM, et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nature Med 1999; 5: 1256-63
29. 29. Gene therapy: a loss of innocence [editorial]. Nat Med 2000; 6: 1
30. 30. Kim CJ, Cormier J, Roden M, et al. Use of recombinant pox-viruses to stimulate anti-melanoma T cell reactivity. Ann Surg Oncol 1998; 5: 64-76
31. 31. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates in p53-deficient human tumor cells. Science 1996; 274: 373-6
32. 32. Hall AR, Dix BR, O'Carroll SJ, et al. p53-dependent cell death/ apoptosis is required for a productive adenovirus infection. Nat Med 1998; 4: 1068-72
33. 33. Kirn D, Nemunaitis J, Ganly I, et al. A phase II trial with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent refractory head and neck cancer [abstract]. Proc Am Soc Clin Oncol 1998; 17: 1509
34. 34. Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-45
35. 35. Freytag SO, Rogulski KR, Paielli DL, et al. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323-33
36. 36. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of relication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 200; 7: 859-66
37. 37. Markert JM, Medlock MD, Rabkin SD. Conditinally relicating herpes simples virus mutant, G207 for the treatment of malignant glioma: results of a phase 1 trial. Gene Ther 200; 7: 867-74
38. 38. Nalbantoglu J, Pari G, Karpali G, et al. Expression of the primary coxsackie and adenovirus receptor is downregulaled during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. Hum Gene Ther 1999; 10: 1009-19
39. 39. Li Y, Rey-Chen P, Bergelson JM, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59: 325-30
40. 40. Gropp R, Michaela F, Wagner TOF, et al. Epithelial defensins impair adenoviral infection: implication for adenovirus-mediated gene therapy. Hum Gene Ther 1999; 10: 957-64
41. 41. Bosse R, Singhofer-Wowra M, Rosenthal F, et al. Good manufacturing practice production of human stem cells for somatic cell and gene therapy. Stem Cells 1997; 15 Suppl. 1: 275-80
42. 42. Linden RM, Woo SLC. Avant-garde gene therapy. Nat Med 1999; 5: 21-2
43. 43. Coffey MC, Strong JE, Forsyth PA, et al. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332-4
44. 44. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-80
45. 45. Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998; 4: 354-7
46. 46. Lunger R. Drug delivery and targeting. Nature 1998; 392 Suppl.: 5-10
47. 47. Tang WH, Xu L, Pirollo KF, et al. A ligand-directed, tumor-targeting systemic gene delivery system [abstract]. Proc Am Assoc Cancer Res 1999; 40: 4167
48. 48. Murray JL, Yoo GH, Lopez-Berestein G, et al. Phase 1 trial of intratumoral liposomal-E1A gene therapy in patients with recurrent/refractory breast cancer (BC) and head and neck (H&N) cancer [abstract). Proc Am Soc Clin Oncol 1998: 17; 1662
49. 49. Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A 1996; 93: 15388-93
50. 50. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2: 985-91
51. 51. Hang Y, Mukhopadhyay T, Donehower LA, et al. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 1993; 4: 451-60
52. 52. Monia BP, Johnston JF, Geiger T, et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 1996; 2: 668-74
53. 53. Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphnma. Lancet 1997, 349: 1137-41
54. 54. Ho PT, Parkinson DR. Antisense oligonucleolides as therapeutics for malignant diseases. Semin Oncol 1997; 24: 187-202
55. 55. Akhtar S, Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol Sci 1997; 18: 12-8
56. 56. Tortora G, Caputo R, Pomatico G, et al. Cooperative inhibitory effect of novel mixed backbone oligonucleolide targeting protein kinase A in combination woth docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clin Cancer Res 1999; 5: 875-81
57. 57. YamamotoT, Yamamoto S, Kalaoka T, et al. Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res Dev 1994; 4: 119-22
58. 58. Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as T helper-1 promoting adjuvants. Nat Med 1997; 3: 849-54
59. 59. Chong H, Vile R. Gene therapy for cancer. Drugs Future 1997; 22: 857-74
60. 60. Perry MA, Todryk S, Dalgleish AG. The role of HSVtk in the treatment of solid tumours. Expert Opin Invest Drugs 1999; 8: 777-85
61. 61. Hamel W, Magnelli L, Chirarugi V, et al. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 1996, 56: 2697-302
62. 62. Craperi D, Vicat JM, Nissou MF, et al. Increased Bax expression is associated with cell death induced by ganciclovir in a herpes thymidine kinase gene-expressing glioma cell line. Hum Gene Ther 1999; 10: 679-88
63. 63. Barba D, Hardin J, Sadelain M, et al. Development of anti-tumorimmunity following thymidinekinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci U S A 1994; 91: 4348-52
64. 64. Izquierdo ML. An overview of gene therapy approaches to neurological malignancies. BioDrugs 1998; 9: 337-49
65. 65. Ram Z, Culver KW, Oshiro ME, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producer cells. Nat Med 1997; 3: 1354-61
66. 66. Klatzmann D, Cherin P, Bensimon G, et al. A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinasc 'suicide' gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Hum Gene Ther 1998; 9: 2585-94
67. 67. Ido A, Nakata K, Kato Y, et al. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res 1995; 55: 3105-9
68. 68. Chen L, Chen D, Manome Y, et al. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 1995; 96: 2775-82
69. 69. Vandier D, Rixe O, Brenner M, et al. Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes sinplex virus-thymidine kinase gene. Cancer Res 1998; 58: 4577-80
70. 70. Mullen C, Kilstrup M, Blaese R. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proe Natl Acad Sci U S A 1992; 89: 33-7
71. 71. Mullen CA, Coale MM, Lowe R, et al. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild-type tumor. Cancer Res 1994; 54: 1503-6
72. 72. Huber BE, Austin KA, Richards CA, et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994; 91: 8302-6
73. 73. Cao G, Kuriyama S, Gao J, et al. Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter. Gene Ther 1999; 6: 83-90
74. 74. Bordignon C, Bonini C, Verzeletti S, et al. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity alter allogeneic bone marrow transplantation. Hum Gene Ther 1995; 6: 813-9
75. 75. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-24
76. 76. Verzeletti S, Bonini C, Marktel S, et al. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum Gene Ther 1998; 9: 2243-51
77. 77. Dalgleish AG, Browning MJ, editors. Tumour immunology: immunotherapy and cancer vaccines. Cambridge: Cambridge University Press, 1996
78. 78. Human gene marker/therapy clinical protocols. Hum Gene Ther 1999; 10: 1043-92
79. 79. Asher AL, Mule JJ, Kasid A, et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha: evidence for paracrine immune effects of tumour necrosis factor-alpha against tumors. J Immunol 1991; 146: 3227-34
80. 80. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403
81. 81. Gansbacher B, Zier K, Daniels B, et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217-24
82. 82. Hock H, Dorsch M, Diamantstein, et al. Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med 1991; 174: 1291-8
83. 83. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90: 3539-43
84. 84. Lim M, Simons JW. Emerging concepts in GM-CSF gene-transduced tumor vaccines for human prostate cancer. Curr Opin Mol Ther 1999; 1: 64-71
85. 85. Dilloo D, Bacon K, Holden W, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 1996; 2: 1090-5
86. 86. Paillard F. Cytokine and chemokine: a stimulating couple. Hum Gene Ther 1999; 10: 695-6
87. 87. Wallich R, Bulbuc N, Hammerling GH, et al. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 1985; 315: 301-5
88. b gene. Proc Natl Acad Sci U S A 1988; 85:4463-7
89. 89. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993; 259: 368-70
90. 90. Putzer BM, Hitt M, Mueller Wl, et al. Interleukin-12 and B7-I costimulatory molecule expressed by an adenoviral vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci U S A 1997; 94: 10889-94
91. 91. Dalgleish AG. The case for therapeutic vaccines. Melanoma Res 1996; 6: 5-10
92. 92. Dalgleish AG. The development of therapeutic vaccines of the management of malignant melanoma. Cancer Surv 1996; 26: 289-319
93. 93. Hrouda D, Dalgleish AG. Gene therapy for prostate cancer. Gene Ther 1996; 3: 845-52
94. 94. Todryk SM, Chong H, Vile RG, et al. Can immunotherapy by gene transfer tip the balance against colorectal cancer? Gut 1998; 43: 445-9
95. 95. Abdel-Wahab Z, Weltz C, Hester D, et al. A phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells. Cancer 1997; 80: 401-12
96. 96. Schreiber S, Kämpgen E, Wagner E, et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Hum Gene Ther 1999; 10: 983-93
97. 97. Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 1998; 95: 13141-6
98. 98. Hennemann B, Andreesen R. Monocyte/macrophage activation by immunostimulators. Clin Immunother 1996; 5: 294-308
99. 99. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-51
100. 100. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998; 46: 82-7
101. 101. Zhong L, Granelli-Piperno A, Choi Y, et al. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 1999; 29: 964-72
102. 102. Diebold S, Lehrmann H, Kursa M, et al. Efficient gene delivery into human dendritic cells by adenovirus polyethylenimine and mannose polyethylenimine transfection. Hum Gene Ther 1999; 10: 775-86
103. 103. Condon C, Watkins SC, Celluzzi CM, et al. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996; 2: 1122-8
104. 104. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumour lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-32
105. 105. Okada H, Tahara H, Shurin MR, et al. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 1998; 78: 196-201
106. 106. Reeves M, Royal R, Lam J, et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 1996; 56: 5672-7
107. 107. Pérez-Díez A, Butterfield LH, Li L, et al. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Cancer Res 1998; 58: 5305-9
108. 108. Uyttenhove C, Maryanski J, Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 1983; 157: 1040-52
109. 109. Topalian SL, Kasid A, Rosenberg SA. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. J Immunol 1990; 144: 4487-95
110. 110. Jäger E, Ringhoffer M, Altmannsberger M, et al. Immunosclection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Can 1997; 71: 142-7
111. 111. Miller PW, Sharma, S, Stolina M, et al. Intratumoral administration of cytokine gene-modified dendritic cells augments antigen presentation and processing in non-small cell lung cancer [abstract]. Proc Am Assoc Cancer Res 1999; 40: 572
112. 112. Cao X, Zhang W, He L, et al. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J Immunol 1998; 161: 6238-44
113. 113. Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T cell receptor genes. Cancer Res 1995; 55: 3369-73
114. 114. Wang G, Chopra RK, Royal RE, et al. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain gene recognising a human ovarian cancer antigen. Nature Med 1998; 4: 168-72
115. 115. Altenschmidt U, Moritz D, Croner B. Specific cytotoxic T lymphocytes in gene therapy. J Mol Med 1997; 75: 259-66
116. 116. Paillard F. Immunotherapy with T cells bearing chimeric antitumor receptors. Hum Gene Ther 1999; 10: 151-3
117. 117. Shiraki K, Tsuji N, Shioda T, et al. Expression of Fas ligand in liver metastases of human colonie adenocarcinomas. Proc Natl Acad Sci U S A 1996; 94: 6420-5
118. 118. McGuiness RP, Ge Y, Patel SD, et al. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther 1999; 10: 165-73
119. 119. Tahara H, Zeh HI, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54: 182-9
120. 120. Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Mod 1996; 2: 1038-41
121. 121. Honon HM, Anderson D, Hernandez P, et al. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding Interferon a. Proc Natl Acad Sci U S A 1999; 96: 1553-8
122. 122. Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst 1998; 90: 273-86
123. 123. Tanaka T, Manome Y, Wen P, et al. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 1997; 3: 437-42
124. 124. Valente P, Fassina G, Melchiori A, et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998; 75: 246-53
125. 125. Baker AH, George SJ, Zaltsman AB, et al. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 1999; 79: 1347-55
126. 126. Rigg AS, Waxman J, Lemoine NR. Gene therapy with TIMP1 or TIMP2 prolongs the survival and reduces the burden of disease for mice harboring intraperitoneal human pancreatic carcinomas [abstract]. Proc Am Assoc Cancer Res 1999; 40: 4169
127. 127. Oku T, Tjuvajec JG, Miyagawa T, et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res 1998; 58: 4185-92
128. 128. Im SA, Gomez-Manzano C, Fueyo J, et al. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 1999; 59: 895-900
129. 129. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor recptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A 1998; 95: 8795-800
130. 130. Machein MR, Risau W, Plate KH. Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum Gene Ther 1999; 10: 1117-28
131. 131. Gabrilovich DI, Ishida T, Nadaf S, et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999; 5: 2963-70
132. 132. Cao Y, O'Reilly MS, Marshall B, et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growlh and produces long-term dormancy of metastases. J Clin Invest 1998; 101: 1055-63
133. 133. Tanaka T, Cao Y, Folkman J, et al. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 1998; 58: 3362-9
134. 134. Chen QR, Kumar D, Stass SA, et al. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 1999; 59: 3308-12
135. 135. Liu Y, Thor A, Shtivelman E, et al. Systemic gene delivery expands the repertoire of effective antiangiogenic agents. J Biol Chem 1999; 274: 13338-44
136. 136. Gottesman M. How cancer cells evade chemotherapy: sixteenth Richard and Hindu Rosenthal Foundation Award Lecture. Cancer Res 1993; 53: 747-54
137. 137. Podda S, Ward M, Himelstein A, et al. Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci U S A 1992; 89: 9676-80
138. 138. Sorrentino BP, Brandt SJ, Bodine D, et al. Selection of drugresistant bone marrow cells in vivo after retroviral transfer of human MDRI. Science 1992; 257: 99-103
139. 139. Rafferty JA, Hickson I, Chinnasamy N, et al. Chemoprotection of normal tissues by transfer of drug resistance genes. Cancer Metastasis Rev 1996; 15: 365-83
140. 140. Hesdorffer C, Ayello J, Ward M, et al. Phase I trial of retroviral-mediated transfer of the human MDRI gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998; 16: 165-72
141. 141. Merrouche Y, Negrier S, Bain C, et al. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. J Clin Oncol 1995; 13: 410-8
142. 142. Brenner MK, Rill DR, Moen RC, et al. Gene marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-6
143. 143. Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukaemia (CML) contribute to relapse after autologous bone marrow transplantation in CML. Blood 1994; 83: 3068-76